FIELD: immunology.
SUBSTANCE: disclosed is a modified T-cell receptor (TCR) and an antigen-binding fragment thereof capable of binding survivin. Also disclosed are compositions targeted on cancer cells, and a method of treating a subject having cancer.
EFFECT: this group of inventions can find further application in cancer therapy.
11 cl, 5 tbl, 9 ex, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CONSTRUCTED HIGH-AFFINITY HUMAN T-CELL RECEPTORS | 2014 |
|
RU2740648C2 |
| SPECIFIC BINDING MOLECULES | 2020 |
|
RU2825837C2 |
| T-CELL COMPOSITIONS WITH T-CELL RECEPTOR DEFICIENCY | 2013 |
|
RU2781979C2 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
| T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| NEW ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION | 2018 |
|
RU2805674C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
